Decontamination of Two Umbilical Cord Blood Grafts Prior to Autologous Administration

Stancioiu, Felician; Bogdan, Raluca Daniela; Bogdan, Bulumac; Ivanescu, Bogdan; Dumitrescu, Radu

doi:10.32388/iumk3s

Cited by 1 publication

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…for immune dysfunction type I: over-activation of pro-inflammatory actions (ex type M1 macrophages) resulting in subacute inflammation (increased TNF-α or α- Administration of autologous cord blood was performed after confirmatory blood group, Rh and HLA typing, with a minimum of 5 x 10 6 TNCs/kg being available in each graft; two grafts were microbiologically contaminated and they were successfully de-contaminated prior to infusion while preserving the viability of stem cells (37). Each cord blood graft was used integrally, meaning that both of the 2 contiguous compartments (20 ml and the 5 ml compartment) were processed by adding Dextran 40 and albumin to minimize the osmotic modifications of the cells post-decryogenation.…”

Section: Materials and Methodmentioning

confidence: 99%

Autologous Cord Blood vs Individualized Supplements in Autistic Spectrum Disease – Results of the CORDUS Study

Stancioiu,

Dumitrescu,

Bogdan

et al. 2024

Preprint

View full text Add to dashboard Cite

Cellular therapies have started an important new therapeutic direction for Autistic Spectrum Disease (ASD), and the ample diversity of ASD pathophysiology and the different types of cell therapies need an equally ample effort for studying the applicable ASD causes and the specific benefits of cell therapies via clinical studies.CORDUS Clinical Study is a crossover study in which autologous cord blood was administered intravenously to 56 patients between January 2019 and July 2023, and has compared its efficacy versus an individualized combination of supplements; both treatments were administered in a different sequence to all participants. Treatment efficacy was evaluated pre- and post- treatments by an independent psychotherapist with ATEC, Q-CHAT and a 16-item comparative table score, after interviews with the children’s parents and therapists.Cord blood was beneficial in the group of 3–7-year-old children (n=28; 3 out of 4 children – 78.57% - improved scores), but was much less effective in kids older than 8 years or with body weight of more than 35 kg (n=28; 1 out of 10 children improved scores). Individualized supplements were more efficacious than cord blood in 5 cases out of 28, while in 23 kids cord blood brought more improvement than supplements; 6 kids registered minor or no improvement. Statistically significant improvements were seen after cord blood infusion on areas such as verbalization and social interaction, but not on irritability or aggressive behavior; also ample individual differences were noted. No serious adverse reactions were noted during and after cord blood or supplement administration.

show abstract

Section: Materials and Methodmentioning

confidence: 99%